, Volume 6, Issue 1, pp 28–42

Multifunctional drugs for head injury

Review Article

DOI: 10.1016/j.nurt.2008.10.036

Cite this article as:
Vink, R. & Nimmo, A.J. Neurotherapeutics (2009) 6: 28. doi:10.1016/j.nurt.2008.10.036


Traumatic brain injury (TBI) remains one of the leading causes of mortality and morbidity worldwide in individuals under the age of 45 years, and, despite extensive efforts to develop neuroprotective therapies, there has been no successful outcome in any trial of neuroprotection to date. In addition to recognizing that many TBI clinical trials have not been optimally designed to detect potential efficacy, the failures can be attributed largely to the fact that most of the therapies investigated have been targeted toward an individual injury factor. The contemporary view of TBI is that of a very heterogenous type of injury, one that varies widely in etiology, clinical presentation, severity, and pathophysiology. The mechanisms involved in neuronal cell death after TBI involve an interaction of acute and delayed anatomic, molecular, biochemical, and physiological events that are both complex and multifaceted. Accordingly, neuropharmacotherapies need to be targeted at the multiple injury factors that contribute to the secondary injury cascade, and, in so doing, maximize the likelihood of a successful outcome. This review focuses on a number of such multifunctional compounds that have shown considerable success in experimental studies and that show maximum promise for success in clinical trials.

Key Words

Neurotrauma statins progesterone erythropoietin cyclosporin toll-like receptors magnesium dexanabinol bradykinin substance P minocycline thyrotropin releasing hormone 
Download to read the full article text

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2009

Authors and Affiliations

  1. 1.School of Medical SciencesUniversity of AdelaideAdelaideAustralia

Personalised recommendations